The role of hematopoietic stem cell (HSC) transplantation has been under continuous expansion and revision in recent decades. Autologous HSC transplants rely primarily on the efficacy of a single (sometimes double) course of high-dose therapy (HDT) to eradicate the disease. The role of the autologous graft is simply limited to restoring hematopoiesis. Autologous HSC transplants can now be performed with transplant-related mortality rates generally well under 5%. Therefore, they have become more attractive to the previously excluded population of patients over age 65.
Standard myeloablative allogeneic HSC transplants add the potential benefit of a graft-vs-tumor effect to the antitumor activity of HDT. However, the high transplant-related mortality associated with this procedure has excluded patients over 55 years of age in most centers and from most clinical trials. In many clinical situations, recognition of the clinical benefits of a strong graft-vs-tumor effect has allowed for a reduction in the intensity of the conditioning regimen, in an attempt to decrease associated morbidity and mortality. The development of nonmyeloablative and reduced-intensity allogeneic HSC transplantation has made this approach feasible for the population of patients over 55 years old.
Critical questions relevant to the older patient are: (1) Can the older individual mobilize sufficient numbers of HSC to functionally restore stable and long-term hematopoiesis in the recipient? (2) Can the older patient tolerate HDT with reasonable safety? (3) Can the older patient expect clinical benefits similar to those demonstrated for young individuals? In this review, we will attempt to answer these questions based on the available data, consisting mainly of retrospective analysis of series with limited numbers of patients. While these studies establish feasibility and document positive outcomes in selected elderly patients, they cannot be used to formulate firm generalized recommendations. The lack of prospective randomized trials including older individuals remains the major impediment to clinical decision-making processes when evaluating elderly patients as candidates for HSC transplantation.
Stem Cell Reserve and Mobilization in the Elderly
A significant decline in hematopoietic reserve has been reported with aging in healthy individuals, raising serious concerns regarding their ability to become HSC donors. This applies to both the elderly patient as a candidate for autologous transplantation and the elderly donor in the allogeneic transplant setting. The issue is particularly valid for autologous transplants, since these patients would have been previously exposed (sometimes extensively) to chemotherapy and/or radiotherapy.
In a mouse model, granulocyte colony-stimulating factor (G-CSF, Neupogen) mobilized significantly larger numbers of HSC and progenitor cells (HPC) in aged mice compared to young animals.[2,3] This was observed despite the presence of mild anemia in the older mice. The higher numbers of HSC were functionally capable of restoring long-term hematopoiesis.
Competitive transplant experiments of mobilized peripheral blood stem cells from young and old mice revealed that 5 months after transplantation, HSC from aged mice contributed an average of 80% of peripheral blood cells (including myeloid cells, T and B lymphocytes) and > 75% of cells from other hematopoietic tissues (spleen, thymus, bone marrow). Enhanced mobilization appeared to be intrinsic to the aged HSC. In addition, adhesion of HSC to stromal cells was impaired in aged mice. This phenomenon was associated with increased levels of active Cdc42, a Rho GTPase involved in cell adhesion. Advanced donor or recipient age impaired homing of HPC to the bone marrow and spleen after transplantation. These experiments appear to document a role for changes with aging in the bone marrow microenvironment.
In healthy humans (aged 16–100 years), the basal numbers of CD34+ cells in peripheral blood decreased significantly as a function of age, particularly in individuals > 80 years old. The number of granulocyte-macrophage colony-forming units (CFU-GM)—but not erythroid burst-forming units (BFU-E) or granulocyte/erythrocyte/monocyte/ megakaryocyte colony-forming units (CFU-GEMM)—per 103 CD34+ cells plated, decreased significantly with age. In both animals and humans, investigators have described an intrinsic loss of T-cell generation capacity in old bone marrow CD34+ cells, with a preferential differentiation toward myeloid cells.
The response of HSC to hematopoietic growth factors may be different in older individuals. After 5 days of low-dose (30 μg) G-CSF administration, HPC measured by the CFU-GM assay increased threefold in young healthy individuals (mean age: 23 years), but this was associated with no significant increase from baseline in older subjects (mean age: 74 years). At standard dosages of G-CSF (300 μg), both young and old individuals experienced a significant increase in the number of CFU-GM in peripheral blood, but the increase was twofold higher in the young.
In spite of these findings, most elderly patients are able to collect adequate numbers of HSC for transplantation, even those who have been previously exposed to myelosuppressive treatments.
Higher numbers of transplanted CD34+ cells result in faster neutrophil and platelet recovery. But no significant impact on transplant-related mortality, response rates or survival has been demonstrated, as long as a minimum of 2 x 103 CD34+ cells per kg are infused.
Analysis of the database of 984 patients with multiple myeloma from the University of Arkansas, which included 106 patients over 70 years of age, revealed that age, more than 12 months of previous chemotherapy, and low platelet counts predicted for poor numbers of CD34+ cell collection. However, 85% of the older patients without the other two adverse factors were able to collect > 4 x 106/kg. There was no effect of age on kinetics of neutrophil engraftment, but platelet recovery was delayed in older patients receiving < 2 x 106 CD34+ cells per kg. This effect of platelet recovery was not observed in patients receiving > 4 x 106 CD34+ cells per kg.
These findings were confirmed by a study of 789 myeloma patients from the Spanish Myeloma Group (median age: 59 years, range: 20–72). After receiving four cycles of multiagent chemotherapy, including several alkylators (cyclophosphamide, melphalan [Alkeran], and carmustine [BCNU]), only 3% of cases could not proceed with transplantion due to a low CD34+ cell yield. On multivariate analysis, only age and time from diagnosis to mobilization were associated with lower numbers of HSC collected.
Similarly, in a study of patients with acute myelogenous leukemia (AML, N = 150) in first complete remission (CR), nearly identical successful rates of CD34+ cell mobilization (87% vs 80%) were observed in patients younger or older than 60.
Related allogeneic HSC donors are usually of similar age with the recipient. Therefore, any differences in engraftment patterns may not only reflect characteristics of the aged donated HSC but also those of the aged microenvironment of the recipient. In a study from the National Marrow Donor Program, matched unrelated grafts from donors aged > 45 years contained slightly lower nucleated cell numbers but resulted in no appreciable differences in engraftment (median age of the recipients was 35, not significantly different between groups). Transplants from older and young donors were associated with significant but small differences in transplant outcomes. Five-year disease-free (DFS) and overall survival (OS) for donors aged > 45 years were 21% and 25%, compared to 29% and 33% for donors aged < 30 years, and 26% and 29% for donors aged 31 to 45 years, respectively. Risk of relapse was not associated with donor age. Older age donor was associated with a higher risk for severe (grade III/ IV) acute and chronic graft-vs-host disease.
The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.
1. Balducci L, Hardy C, Lyman G: Hematopoiesis and aging. Cancer Treat Res 124:189-221, 2005.
2. Xing Z, Ryan M, Daria D, et al: Increased hematopoietic stem cell mobilization in aged mice. Blood 108:2190-2197, 2006.
3. Liang Y, Van Zant G, Szilvassy S: Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 106:1479-1487, 2005.
4. Moresi R, Tesei S, Costarelli L, et al: Age- and gender-related alterations of the number and clonogenic capacity of circulating CD 34+ progenitor cells. Biogerontology 6:185-192, 2005.
5. Chatta G, Price T, Allen R, et al: Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 84:2923-2929, 1994.
6. Klaus J, Herrmann D, Breitkreutz I, et al: Effect of CD 34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 78:21-28, 2006.
7. Morris C, Siegel E, Barlogie B, et al: Mobilization of CD 34+ cells in elderly patients (≥ 70 years) with multiple myeloma: Influence of age, prior therapy, platelets count and mobilization regimen. Br J Haematol 120:413-423, 2003.
8. de la Rubia J, Blade J, Lahuerta J, et al: Effect of chemotherapy with alkylating agents on the yield of CD 34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica 91:621-627, 2006.
9. Ferrara F, Viola A, Copia C, et al: Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia. Hematol Oncol 25:84-89, 2007.
10. Kollman C, Howe C, Anasetti C, et al: Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98:2043-2051, 2001.
11. Kusnierz-Glaz CR, Schlegel PG, Schriber R, et al: Influence of age on the outcome of 500 autologous marrow transplant procedures for hematological malignancies. J Clin Oncol 15:18-25, 1997.
12. Mileshkin LR, Seymour JF, Wolf MM, et al: Cardiovascular toxicity is increased, but mananeable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma 46:1575-1579, 2005.
13. Mazza P, Palazzo G, Amurri B, et al: Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: An interim report. Bone Marrow Transplant 23:1273-1278, 1999.
14. Jantunen E, Mahlamaki E, Nousiainen T: Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patiens (>60 years) with non-Hodgkin's lymphoma: Comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant 2000; 26:737-741.
15. Jantunen E, Kuittinen T, Penttila K, et al: High-dose melphalan (200 mg/m2 ) supported by autologous stem cell transplantation is safe and effective in elderly (> or = 65 years) myeloma patients: Comparison with younger patients treated on the same protocol. Bone Marrow Transplant 37:917-922, 2006.
16. Badros A, Barlogie B, Siegel E, et al: Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114:600-607, 2001.
17. Gopal AK, Gooley TA, Golden JB, et al: Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 27:593-599, 2001.
18. Olivieri A, Capelli D, Montanari M, et al: Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: A single center experience. Bone Marrow Transplant 27:1189-1195, 2001.
19. Yanada M, Emi N, Naoe T, et al: Allogeneic myeloablative transplantation for patients aged 50 year and over. Bone Marrow Transplant 34:29-35, 2004.
20. Aylea EP, Kim HT, Ho V, et al: Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105:1810-1814, 2005.
21. Scott BL, Sandmaier BM, Storer B, et al: Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic sendrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 20:128-135, 2006.
22. Aoudihane M, Labopin M, Gorin NC, et al: Comparative outcome od reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation. Leukemia 19:2304-2312, 2005.
23. Canals C, Martino R, Sureda A, et al: Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Exp Hematol 31:1039-1043, 2003.
24. Corradini P, Zallio F, Mariotti J, et al: Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol 23:6690-6698, 2005.
25. Gómez-Núñez M, Martino R, Caballero MD, et al: Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results from the Spanish multicenter prospective trial. Bone Marrrow Transplant 33:477-482, 2004.
26. Sorror M, Maris M, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005.
27. Giles F, Borthakur G, Ravandi F, et al: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624-627, 2007.
28. Kassar M, Gregory S, Shell K, et al: Assessing the impact of comorbidities on autologous hematopoietic cell transplant (AHCT) outcomes using the hematopoietic cell transplant-comorbidity index (HCT-CI) in lymphoma (abstract 7102). J Clin Oncol 25(18S):382s, 2007.
29. Ferrara F, Palmieri S, Clementano M, et al: Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leuk Lymphoma 47:1593-1598, 2006.
30. Oriol A, Ribera J, Esteve J, et al: Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Hematologica 89:791-800, 2004.
31. Thomas X, Suciu S, Rio B, et al: Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: Results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 92:389-396, 2007.
32. Gorin N, Labopin M, Pichard P, et al: Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: Importance of the source of stem cells. Br J Haematol 110:887-893, 2000.
33. Deeg H, Shulman H, Anderson J, et al: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95:1188-1194, 2000.
34. Gupta V, Daly A, Lipton J, et al: Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 11:764-772, 2005.
35. Niederwieser D, Becker C, Krahl R, et al: Hematopoietic cell transplantation (HCT) after low-dose, total body irradiation-based regimen increased leukemia-free survival (LFS) in elderly patients with cytogenetic high-risk AML compared to chemotherapy (OSHO 97 study) (abstract 7003). J Clin Oncol 25(18S):357s, 2007.
36. Hamaki T, Kami M, Kanda Y, et al: Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: A retrospective study of 33 patients. Bone Marrow Transplant 35:549-556, 2005.
37. Siegel DS, Desikan KR, Mehta J, et al: Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1:51-54, 1999.
38. Reece DE, Bredeson C, Perez WS, et al: Autologous stem cell transplantation in multiple myeloma patients <60 vs >60 years of age. Bone Marrow Trasplant 32:1135-1143, 2003.
39. Lenhoff S, Hjorth M, Westin J, et al: Impact of age on survival after intensive therapy for multiple myeloma: A population-based study by the Nordic Myeloma Study Group. Br J Haematol 133:389-396, 2006.
40. Gertz MA, Lacy MQ, Dispenzieri A, et al: Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 39:605-611, 2007.
41. Badros A, Barlogie B, Siegel E, et al: Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114:600-607, 2001.
42. Arora M, McGlave PB, Burns LJ, et al: Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant 35:1133-1140, 2005.
43. Crawley C, Iacobelli S, Bjorkstrand B, et al: Reduced-intensity conditioning for myeloma: Lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109:3588-3594, 2007.
44. Bruno B, Rotta M, Patriarca F, et al: A comparison of allorafting with autografting for newly diagnosed myeloma. N Engl J Med 356:1110-1120, 2007.
45. Jantunen E, Hala M, Juvonen E, et al: Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: A nation-wide analysis. Bone Marrow Transplant 37:367-372, 2006.
46. Gopal AK, Rajendran JG, Gooley TA, et al: High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 25:1396-1402, 2007.
47. Bitran JD, Klein L, Link D, et al: High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 9:383-388, 2003.
48. Seldin DC, Anderson JJ, Skinner M, et al: Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 108:3945-3947, 2006.
49. Brown JR, Kim HT, Stephans K, et al: Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12:1056-1064, 2006.
50. Kerbauy DMB, Gooley TA, Sale GE, et al: Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocytemia. Biol Blood Marrow Transpant 13:355-365, 2007.